RPS6 and neoplasm: This study reports the first evidence that M-COPA decreased the level of cell surface expression of EGFR harboring an activating mutation (Figure 1A), abrogated its downstream oncogenic signals represented by a reduction of the phosphorylated forms of Akt, S6, MEK and ERK (Figure 1B), and ultimately suppressed tumor growth in EGFR-activated NSCLC cell lines (Figure 2A).